Voya Investment Management LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 16.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,770,650 shares of the company’s stock after buying an additional 395,762 shares during the quarter. AbbVie accounts for about 0.7% of Voya Investment Management LLC’s holdings, making the stock its 27th biggest holding. Voya Investment Management LLC’s holdings in AbbVie were worth $724,123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of the stock. Bogart Wealth LLC increased its position in shares of AbbVie by 1.6% during the third quarter. Bogart Wealth LLC now owns 45,821 shares of the company’s stock valued at $11,986,000 after acquiring an additional 723 shares during the last quarter. McLaughlin Asset Management Inc. raised its stake in shares of AbbVie by 5.1% in the 3rd quarter. McLaughlin Asset Management Inc. now owns 3,893 shares of the company’s stock valued at $1,018,000 after acquiring an additional 188 shares during the period. Prasad Wealth Partners LLC raised its stake in shares of AbbVie by 51.9% in the 3rd quarter. Prasad Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $532,000 after acquiring an additional 694 shares during the period. FreeGulliver LLC lifted its holdings in shares of AbbVie by 12.9% in the 3rd quarter. FreeGulliver LLC now owns 1,281 shares of the company’s stock worth $335,000 after acquiring an additional 146 shares during the last quarter. Finally, BCGM Wealth Management LLC acquired a new position in shares of AbbVie in the 3rd quarter worth approximately $239,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie News Roundup
Here’s some of the latest news about ABBV:
- Positive Sentiment: Barclays raised its price target to $335 from $325 and maintained an Overweight rating, signaling continued analyst confidence in AbbVie’s outlook. Article: AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
- Positive Sentiment: New AI drug-discovery work with Iambic and expanded rights to Brise’s preclinical migraine programs broaden AbbVie’s research pipeline, particularly in neuroscience. These efforts may support future growth, though they are early-stage. Article: AbbVie Expands Its Pipeline With New AI Drug Discovery Partnerships
- Neutral Sentiment: A report said ETFs were net sellers of AbbVie shares on Nov. 12, but the provided information does not specify the scale or whether the selling reflects a lasting change in investor sentiment. Article: ETFs Are Net Sellers of AbbVie on Nov. 12
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $275.00 price objective on shares of AbbVie in a research report on Monday, November 2nd. Royal Bank Of Canada boosted their target price on AbbVie from $280.00 to $330.00 and gave the company an “outperform” rating in a research report on Monday, November 2nd. Morgan Stanley upped their price target on AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. The Goldman Sachs Group upped their price target on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research note on Friday, October 23rd. Finally, Canaccord Genuity Group raised their price target on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $297.85.
Check Out Our Latest Stock Report on AbbVie
AbbVie Price Performance
NYSE ABBV opened at $292.40 on Wednesday. The company has a market cap of $516.85 billion, a P/E ratio of 50.33, a P/E/G ratio of 1.34 and a beta of 0.20. The stock has a 50-day moving average of $277.14 and a two-hundred day moving average of $241.64. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter in the prior year, the company earned $1.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current fiscal year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is currently 119.10%.
Insiders Place Their Bets
In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Recommended Stories
- Five stocks we like better than AbbVie
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
